# US 6,730,775 B1 · Methods for limiting scar and adhesion formation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,775 B1
- Document ID: US6730775B1
- Status: Granted
- Kind: B1
- Application number: 09/532,221
- Filed: 2000-03-22
- Granted: 2004-05-04
- Earliest claimed: 1999-03-23
- Assignees: University of Southern California
- Inventors: Kathleen E. Rodgers; Gere diZerega
- Web page: https://patentgrep.com/patent/US6730775B1

## CPC

- A61K 38/085: {Angiotensins}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides methods, kits, and pharmaceutical compositions for limiting scar or adhesion formation by administration of angiotensinogen, AI, AI analogues, and/or AI fragments and analogues thereof, AII analogues, AII fragments or analogues thereof, ACE inhibitors, AII AT2 type 2 receptor agonists, either alone or in combination with other compounds.

## Claims

### Claim 1

A method for limiting scar or adhesion formation, comprising administering to a mammal in need thereof an amount effective to limit scar or adhesion formation of at least one active agent comprising a sequence of at least five contiguous amino acids of SEQ ID NO:41.

### Claim 2 (depends on 1)

The method of claim 1 further comprising administering an amount effective to limit scar or adhesion formation of at least one other anti-scarring or anti-adhesion compound.

### Claim 3 (depends on 1)

The method of claim 1, wherein the active agent comprises a sequence of at least six contiguous amino acids of SEQ ID NO:41.

### Claim 4 (depends on 1)

The method of claim 1, wherein the active agent comprises the sequence of SEQ ID NO:41.

### Claim 5 (depends on 1)

The method of claim 1, wherein the active agent comprises a sequence consisting of at least five contiguous amino acids of SEQ ID NO:41.

### Claim 6 (depends on 1)

The method of claim 1, wherein the active agent consists of at least six contiguous amino acids of SEQ ID NO: 41.

### Claim 7 (depends on 1)

The method of claim 1, wherein the active agent consists of the sequence of SEQ ID NO: 41.

### Claim 8 (depends on 1)

The method of claim 1, wherein the method is for limiting scar formation.

### Claim 9

The method of 8, wherein the scar is an existing scar.

### Claim 10 (depends on 1)

The method of claim 1, wherein the method is for limiting adhesion formation.

### Claim 11 (depends on 1)

The method of claim 1, wherein the active agent is administered topically.

### Claim 12 (depends on 1)

The method of claim 1, wherein the active agent is administered transdermnally.

### Claim 13 (depends on 1)

The method of claim 1, wherein the active agent is administered systemically.

### Claim 14 (depends on 1)

The method of claim 1, wherein the mammal is a human.

### Claim 15 (depends on 10)

The method of claim 10, wherein the mammal is a human, and wherein the human will undergo, is undergoing or has undergone a treatment selected from the group consisting of abdominal surgery, cosmetic surgery, gynecological surgery, thoracic surgery, orthopedic surgery affecting tendons or ligaments, neurological surgery affecting the dura mater, laminectomies, discectomies, arthroscopic surgery, and female infertility treatment.

### Claim 16 (depends on 15)

The method of claim 15, wherein the human has peri-spinal adhesions, or peri-neural adhesions.

### Claim 17 (depends on 15, 16)

The method of claim 15 or 16 wherein the active agent is administered topically.

### Claim 18 (depends on 15, 16)

The method of claim 15 or 16 wherein the active agent is administered transdermally.

### Claim 19 (depends on 15, 16)

The method of claim 15 or 16 wherein the active agent is administered systemically.
